EUCTR2007-001159-20-GB进行中（未招募）1 期
A Prospective, Multi-centre, Single-Arm, Open Label Study of the Long term Use of a LHRH Agonist (Decapeptyl® SR, 11.25 mg) in Combination with Livial® Add-back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre-Menopausal Women - HRT Add-back therapy in the management of CCPP using Decapeptyl
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •The patient must have given written (personally signed and dated) informed consent given before completing any study-related procedure, which means any assessment or evaluation that would not have formed part of their normal medical care.
- •The patient must be aged between 18 and 45 years inclusive.
- •The patient must have a clinical diagnosis of Chronic Cyclical Pelvic Pain (CCPP) of at least 6 months duration (with or without evidence of endometriosis).
- •The patient must have had investigations for possible endometriosis within three years prior to the Screening visit.
- •The patient must have had a regular menstrual cycles (between 24 and 42 days) for the 3 months prior to screening.
- •Treatment with a LHRHa is indicated for the patient.
- •The patient must be able to understand, and willing to comply with the requirements of the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The patient has been treated with any LHRHa within 6 months prior to screening.
- •The patient has been treated with Danazol, gestrinone or cyproterone acetate within the 6 months prior to screening or anticipated requirement during the study.
- •The patient has used cyclical progestogens or combined oral contraceptives within one full menstrual cycle (including a spontaneous bleed) prior to screening, or anticipated requirement for these treatments during the study period.
- •The patient is treated with any other medication for CCPP (other than analgesics) within three months prior to screening.
- •The patient has continuous or acyclic pelvic pain.
- •The patient has known metabolic bone disease.
- •The patient has an abnormal full blood count or liver or renal function at screening or within the 6 months prior to screening.
- •The patient has unexplained vaginal bleeding.
- •The patient has a bone mineral density age adjusted T-Score of -2 or below at the Screening visit.
- •The patient has any other medical condition or abnormality that in the opinion of the investigator would impact upon the safety or efficacy of the study treatment or any study assessments.
- •The patient is receiving concomitant treatment with coumarin or indanedione derivatives.
- •The patient has a known contraindication, allergy or hypersensitivity to any of the test compounds or materials (including both Decapeptyl SR and Livial).
- •The patient is pregnant or lactating. Female patients of child-bearing potential (i.e. who are not surgically sterile) must have a negative urine pregnancy test at the Baseline visit.
- •The patient is planning a pregnancy within 31 months of screening.
- •The patient is of child-bearing potential and is unwilling to use adequate barrier contraception for the duration of the study.
- •The patient has received any investigational drug therapy within 30 days prior to the study, or is scheduled to receive such a drug during the study period.
- •The patient has previously entered this study.
研究者
相似试验
尚未招募
不适用
Treatment of Adolescent Idiopathic Scoliosis Using the Ellipse MAGEC SystemAdolescent Idiopathic ScoliosisMusculoskeletal - Other muscular and skeletal disordersACTRN12612000373875Ellipse Technologies, Inc.20
已完成
4 期
This study will be conducted to understand side effect and effectiveness of marketed medicine DenosuRel which prevent the bone related events which are arises when cancer spreads to bonesCTRI/2021/06/034402Reliance Life Sciences Pvt Ltd RLS220
已完成
4 期
The purpose of this research study is to evaluate safety and efficacy of RanizuRelTM containing Ranibizumab for intra-vitreal injection, manufactured by Reliance Life Sciences, Pvt. Ltd. India in patients with neovascular (wet) age-related macular degeneration.CTRI/2021/06/033972Reliance Life Sciences Pvt Ltd220
招募中
1 期
A Prospective, Open, Single-Arm, Multi-Center Clinical Study on the Efficacy and Safety of Pi-Yan-Ning Decoction in the Treatment of Grade III Skin Rash Induced by Anti-Tumor Targeted DrugsITMCTR2000003532The First Affiliated Hospital of Zhejiang Chinese Medical University
已完成
4 期
Post Marketing Observational Study to Assess the Effectiveness and Safety of Prochlorperazine In Patients with Acute VertigoCTRI/2022/01/039287Abbott Healthcare Pvt Ltd